Chonseng Pharmaceutical: Core patent of subsidiary RAY1225 project authorized in Japan

Zongsheng Pharmaceutical announced that its holding subsidiary Zongsheng Ruichuang has received a patent certificate issued by the Japan Patent Office. The patent is titled "Preparation of Polypeptides and Their Use," with patent number 7672503 and a filing date of May 30, 2022. The patent holder is Zongsheng Ruichuang, and the patent term is twenty years from the filing date. This patent is for a compound in the RAY1225 project and is considered a core patent of the project. RAY1225 injection is a peptide drug with dual activation activity on GLP-1 and GIP receptors, currently in phase III clinical trials. The patent authorization will help the company further enhance its intellectual property protection system and leverage its advantages in independent intellectual property, but will not have a significant impact on the company's short-term financial condition or business performance.